ReviewFrontiers in pediatrics2019
To Be Oats or Not to Be? An Update on the Ongoing Debate on Oats for Patients With Celiac Disease.
Review in Frontiers in pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Effects of Selected Cereal Concentrates and a Gluten-Free Diet on Ovarian, Testicular, and Thyroid Gland Morphology.Physiological research · 2026Article
- The follow-up of patients with celiac disease.Journal of translational autoimmunity · 2025Review
- Dietary assessments in individuals living with coeliac disease: key considerations.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Review
- Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies.Nutrients · 2024Review
- The effectiveness of gluten-free dietary interventions: A systematic review.Frontiers in psychology · 2023Review
- Quantification of Barley Contaminants in Gluten-Free Oats by Four Gluten ELISA Kits.Journal of agricultural and food chemistry · 2022Article
- A Review of Health-Beneficial Properties of Oats.Foods (Basel, Switzerland) · 2021Review
- Gluten-Free Cereal Products and Beverages: A Review of Their Health Benefits in the Last Five Years.Foods (Basel, Switzerland) · 2021Review
- Review
- The Gluten Gene: Unlocking the Understanding of Gluten Sensitivity and Intolerance.The application of clinical genetics · 2021Review
- Oats as a Safe Alternative to Triticeae Cereals for People Suffering from Celiac Disease? A Review.Plant foods for human nutrition (Dordrecht, Netherlands) · 2020Review
- Commentary: To Be Oats or Not to Be? An Update on the Ongoing Debate on Oats for Patients With Celiac Disease.Frontiers in pediatrics · 2020Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, the only known effective treatment for celiac disease (CD) is a strict gluten-free diet (GFD) for life. Patients with CD often find it difficult to adhere to strict GFD. Oats, compared with wheat, barley, and rye, contain less amounts of prolamins. Inclusion of oats in a GFD might be valuable due to their nutritional and health benefits and increase of food variety. Therefore, they may potentially improve feeding diversity for these children and improve taste and satiety. We reviewed the literature to evaluate the safety of oats in CD patients. We have searched PUBMED, societal guidelines and national health authorities' recommendations. The following aspects were reviewed: gastrointestinal symptoms, malabsorption, serology including specific avenin antibodies, mucosal changes, avenin toxicity, immunogenicity of oats, and quality of life. We also referred to wheat contamination of oat products, the safe amount of oats for CD patients and the type of oats recommended. Data support that pure oats are well-tolerated by most CD patients, at moderate amounts (20-25 g/day dry rolled oats for children; 50-70 g/day for adults). Nevertheless, since the potential for sensitivity/toxicity exists, oats should be added with caution to a GFD, only after all CD symptoms including weight loss and growth disturbances have resolved, after at least 6 months of conventional GFD and probably also after normalization of serology. The need for pre exposure biopsy is unclear and should be considered on an individual basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.